Full-Time

Senior Director

Forecasting

Confirmed live in the last 24 hours

Insmed

Insmed

501-1,000 employees

Develops therapies for rare diseases

Compensation Overview

$207k - $289.9k/yr

+ Bonus + Equity Awards

Senior, Expert

Bridgewater Township, NJ, USA

In Person

May require some travel.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree in Business, Finance, Engineering or related discipline required (MS, PhD, MBA or other advanced degree preferred)
  • 10+ years of leadership experience in demand forecasting within a pharmaceutical/biotech company or healthcare consulting firm (will consider related experience)
  • Extensive knowledge of pharmaceutical data (e.g., sales, specialty pharmacy, payer, promotional & marketing data, longitudinal patient-level data)
  • Experience with launches and commercialization of pharmaceutical products (specialty drug/respiratory launch experience preferred)
  • Strong blend of technical proficiency, business acumen, and experience informing business growth and opportunity
  • Experience within the US market (experience with global markets beneficial)
  • Expertise in developing product forecasts, market assessments, and competitive intelligence analyses
  • Proven track-record of working with senior leadership on forecast development and communication
  • Strong quantitative and analytical skills, with the ability to translate complex data into actionable insights
  • Collaborative and influential leadership style, with the ability to build strong partnerships across the organization
Responsibilities
  • Leading development of US forecasts across multiple products and indications, as well as guiding and maintaining forecast models across regions
  • Collaborating closely with regional Commercial Effectiveness teams to ensure consistency of forecast assumptions across countries, when possible, and to ensure clear messaging
  • Leading the consolidation of global forecasts and maintaining an up-to-date view of key risks and opportunities in the short, mid and long-term
  • Driving consolidation and delivery of the forecast narrative to senior leadership
  • Proposing methodology, process improvements, and technology solutions, then getting buy-in from cross-functional leaders and leading implementation of such solutions
  • Integrating secondary data analyses and primary market research insights to support forecast assumptions
  • Collaborating with analytic teams on the tracking of product performance vs. forecast expectations
  • Working closely with vendor partners to identify analogs and benchmarks to support forecast assumptions
  • Sharing best practices, innovating, driving efficiencies, and partnering with regional forecasting teams
  • Staying updated on market evolutions and dynamics relevant to Insmed products/pipeline, proactively updating forecasts with material market events
Desired Qualifications
  • Experience with launches and commercialization of pharmaceutical products (specialty drug/respiratory launch experience preferred)
  • Experience with advanced analytical modeling

Insmed develops therapies for patients with serious and rare diseases. The company focuses on unmet medical needs and has a pipeline of clinical trials and approved treatments. Its products work by targeting specific conditions that currently lack effective treatments, and Insmed generates revenue through the sale of these therapies. What sets Insmed apart from competitors is its strong commitment to patient care and its global presence, with offices in the US, Europe, and Japan. The goal of Insmed is to address diverse healthcare challenges and improve the lives of patients with rare diseases.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Richmond, Virginia

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Positive Phase IIb results for TPIP boost Insmed's stock by 29% in 2025.
  • Insmed raised $750 million, enhancing its financial position for future developments.
  • ARIKAYCE's revenue growth reflects strong market demand and successful commercialization.

What critics are saying

  • Delays in Phase 3 trials could impact Insmed's market entry timelines.
  • Heavy reliance on ARIKAYCE poses a risk if market conditions change.
  • Shareholder dilution from the $750 million offering may affect stock value.

What makes Insmed unique

  • Insmed focuses on rare diseases with significant unmet medical needs.
  • The company has a global presence with offices in the US, Europe, and Japan.
  • Insmed's pipeline includes innovative therapies like treprostinil palmitil inhalation powder.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Health Insurance

Paid Vacation

Employee Stock Purchase Plan

Company Equity

Company News

Citeline
Jun 12th, 2025
Insmed Raises $750m After Positive Data

Insmed raised $750 million after positive Phase IIb data for treprostinil palmitil inhalation powder in pulmonary arterial hypertension, boosting its stock by 29% to $90.93. The company sold 7.81 million shares at $96 each in a follow-on public offering. This comes 13 months after a previous offering of 12.62 million shares at $51.50.

PR Newswire
Jun 12th, 2025
Insmed Announces Pricing of $750 Million Public Offering of Common Stock

The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately $750 million.

ROI-NJ
Jun 11th, 2025
Bridgewater-Based Insmed Reports Positive Phase 2B Results For Pulmonary Arterial Hypertension Treatment

Insmed –Insmed Inc., a global biopharmaceutical company, Tuesday announced positive topline results from its Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension (PAH).The results of the double-blind, placebo-controlled study demonstrated the durability of TPIP’s therapeutic effect as a once-daily therapy based on efficacy being evaluated about 24 hours after therapy was administered.Based on these results, Insmed will engage with the Food and Drug Administration regarding the Phase 3 trial design for pulmonary arterial hypertension. Insmed plans to initiate a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of 2025 and a Phase 3 trial in patients with PAH in early 2026.Pulmonary arterial hypertension is a progressive, rare disease in which the blood vessels in the lungs narrow or become obstructed, leading to high blood pressure in the pulmonary arteries. The most common symptoms include shortness of breath, chest pain, dizziness or fainting, fatigue, and weakness. It is estimated that about 35,000 patients in the U.S. have been diagnosed with the disease. Untreated, PAH can be debilitating and often fatal.“The statistically significant and clinically meaningful results shown with TPIP in pulmonary arterial hypertension mark a potential breakthrough for patients and the future of prostanoid therapy,” said Gene Sullivan, chief product strategy officer of Insmed.The study was conducted at 44 sites globally; 102 patients were randomized to receive either TPIP or placebo for 16 weeks

MarketScreener
Apr 29th, 2025
Insmed To Present at the BofA Securities 2025 Health Care Conference

BRIDGEWATER, N.J., April 29, 2025 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the BofA Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025, at 2:20 p.m. PT.

ETF Daily News
Mar 7th, 2025
Proficio Capital Partners LLC Invests $1.86 Million in Insmed Incorporated (NASDAQ:INSM)

Proficio Capital Partners LLC invests $1.86 million in Insmed Incorporated (NASDAQ:INSM).